The retrospective analysis, published in the Journal of Clinical Medicine, supports the use of tildrakizumab, an interleukin-23 (IL-23) inhibitor that was FDA approved in 2018 for moderate-to-severe ...

The HELIOS-B trial previously showed that vutrisiran (Amvuttra; Alnylam Pharmaceuticals), a gene-silencing therapy that ...

Adults with allergic rhinitis experience diagnostic delays and limited access to allergen immunotherapy, impacting quality of life and treatment satisfaction. ICE activity in Minnesota healthcare ...

Dermatology is entering a "biological revolution," with engineered tissues and bio-machines offering new therapeutic ...

Targeted therapies for MASH show progress, with pegozafermin leading in efficacy for fibrosis regression and disease resolution. New research highlights the effectiveness of targeted therapies for ...

Access to biologic therapy, such as omalizumab, is a significant barrier for CSU patients in Latin America, despite high disease knowledge. Participants in the pilot program had high baseline ...

The rapid proliferation of high-efficacy disease-modifying therapies for multiple sclerosis (MS) has revolutionized the treatment landscape, yet significant gaps remain in how health systems organize ...

This transcript has been lightly edited for clarity; captions are auto-generated.

An article published in TechTarget referenced a study published in the January 2026 issue of The American Journal of Managed ...